Elucidating Substrate and Inhibitor Binding Sites on the Surface of GSK-3β and the Refinement of a Competitive Inhibitor

被引:27
|
作者
Licht-Murava, Avital [1 ]
Plotkin, Batya [1 ]
Eisenstein, Miriam [2 ]
Eldar-Finkelman, Hagit [1 ]
机构
[1] Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, IL-69978 Tel Aviv, Israel
[2] Weizmann Inst Sci, Dept Chem Res Support, IL-76100 Rehovot, Israel
关键词
protein kinase; molecular modeling; structure/function; inhibitors; drug design; parasite GSK-3; GLYCOGEN-SYNTHASE KINASE-3; INSULIN-RECEPTOR SUBSTRATE-1; PROTEIN-KINASE; PEPTIDE INHIBITORS; DRUG TARGET; PHOSPHORYLATION; GSK3; GLYCOGEN-SYNTHASE-KINASE-3; SPECIFICITY; MECHANISM;
D O I
10.1016/j.jmb.2011.02.036
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A molecular understanding of substrate recognition of protein kinases provides an important basis for the development of substrate competitive inhibitors. Here, we explored substrate recognition and competitive inhibition of glycogen synthase kinase (GSK)-3 beta using molecular and computational tools. In previous work, we described Gln89 and Asn95 within GSK-3 beta as important substrates binding sites. Here, we show that the cavity bordered by loop 89-QDKRFICN-95, located in the vicinity of the GSK-3 beta catalytic core, is a promiscuous substrate binding subsite. Mutations within this segment highlighted Phe93 as an additional essential contact residue for substrates' recognition. However, unlike Gln89 and Asn95, Phe93 was also important for the binding of our previously described substrate competitive inhibitor, L803 [KEAPPAPPQS(p)P], and its cell-permeable variant L803-mts. The effects of the substitution of charged or polar residues within L803 further suggested that binding to GSK-3 beta is governed by hydrophobic interactions. Our computational model of GSK-3 beta bound to L803 was in agreement with the experimental data. It revealed L803 binding with a hydrophobic surface patch and identified interactions between Pro8 (L803) and Phe93 (GSK-3 beta). Computational modeling of new L803 variants predicted that inhibition would be strengthened by adding contacts with Phe93 or by increasing the hydrophobic content of the peptide. Indeed, the newly designed L803 variants showed improved inhibition. Our study identified different and overlapping elements in GSK-3 beta substrate and inhibitor recognition and provides a novel example for model-based rational design of substrate competitive inhibitors for GSK-3. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:366 / 378
页数:13
相关论文
共 50 条
  • [1] Elucidating gsk-3 substrate and inhibitor binding sites as a tool for inhibitor refinement
    Licht-murava, A.
    Plotkin, B.
    Eisenstein, M.
    Eldar-Finkelman, H.
    MOLECULAR BIOLOGY OF THE CELL, 2012, 23
  • [2] Elucidating the relationship between substrate and inhibitor binding to the active sites of tetrameric β-galactosidase
    Mogalisetti, Pratyusha
    Gorris, Hans H.
    Rojek, Marcin J.
    Walt, David R.
    CHEMICAL SCIENCE, 2014, 5 (11) : 4467 - 4473
  • [3] Substrate Competitive GSK-3 Inhibitors - strategy and Implications
    Eldar-Finkelman, Hagit
    Licht-Murava, Avital
    Pietrokovski, Shmuel
    Eisenstein, Miriam
    BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2010, 1804 (03): : 598 - 603
  • [4] Activator or inhibitor? GSK-3 as a new drug target
    Takahashi-Yanaga, Fumi
    BIOCHEMICAL PHARMACOLOGY, 2013, 86 (02) : 191 - 199
  • [5] Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake
    Zhang, Peng
    Li, Shufen
    Gao, Yang
    Lu, Wenbo
    Huang, Ke
    Ye, Deyong
    Li, Xi
    Chu, Yong
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (24) : 5639 - 5643
  • [6] Acceleration of bone regeneration by topical application of GSK-3 inhibitor
    Arioka, Masaki
    Takahashi, Fumi
    Sasaki, Masanori
    Sasaguri, Toshiyuki
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2014, 124 : 95P - 95P
  • [7] The GSK-3 inhibitor BIO promotes proliferation in mammalian cardiomyocytes
    Tseng, Ai-Sun
    Engel, Felix B.
    Keating, Mark T.
    CHEMISTRY & BIOLOGY, 2006, 13 (09): : 957 - 963
  • [8] GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis
    Yost, C
    Farr, GH
    Pierce, SB
    Ferkey, DM
    Chen, MM
    Kimelman, D
    CELL, 1998, 93 (06) : 1031 - 1041
  • [9] Treatment with GSK-3 substrate-competitive inhibitor reduces neurotoxic brain Aβ levels and improves cognition in Alzheimer's disease animal model
    Avrahami, L.
    Farfara, D.
    Trudler, D.
    Frenkel, D.
    Eldar-Finkelman, H.
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2012, 48 : S9 - S10
  • [10] Pim Kinase Inhibitor Enhances FLT3 Inhibitor Efficacy through GSK-3β Activation and GSK-3β-Mediated Proteasomal Degradation of c-Myc
    Lee, Jonelle K.
    Scarpa, Mario
    Chatterjee, Aditi
    Ali, Moaath Mustafa
    Singh, Prerna
    Kapoor, Shivani
    Trotta, Rossana
    Baer, Maria R.
    BLOOD, 2021, 138